EC Number | Application | Comment | Organism |
---|---|---|---|
2.7.1.39 | drug development | molecular modeling and simulation study of homoserine kinase as an effective leishmanial drug target | Leishmania major |
EC Number | Inhibitors | Comment | Organism | Structure |
---|---|---|---|---|
2.7.1.39 | (1R,3r,5S)-8-[(1-cyclohexyl-1H-tetrazol-5-yl)methyl]-3-(pyridin-3-yl)-8-azabicyclo[3.2.1]octan-3-ol | - |
Leishmania major | |
2.7.1.39 | (2S)-1-(9H-carbazol-9-yl)-3-(piperazin-1-yl)propan-2-ol | - |
Leishmania major | |
2.7.1.39 | (naphthalen-1-yl)(1,3,5-triazatricyclo[3.3.1.13,7]decan-7-yl)methanone | - |
Leishmania major | |
2.7.1.39 | 1-(3,4-dihydroquinolin-1(2H)-yl)-2-[[1-(4-methylphenyl)-1H-tetrazol-5-yl]sulfanyl]ethan-1-one | - |
Leishmania major | |
2.7.1.39 | 1-[(2R,6S)-2,6-dimethylpiperidin-1-yl]-2-[([1,2,4]triazolo[4,3-a]pyrimidin-3-yl)sulfanyl]ethan-1-one | - |
Leishmania major | |
2.7.1.39 | 1-[(2R,6S)-2,6-dimethylpiperidin-1-yl]-2-[4-(4-methylbenzoyl)piperidin-1-yl]ethan-1-one | - |
Leishmania major | |
2.7.1.39 | 2-[(5-amino-4-phenyl-4H-1,2,4-triazol-3-yl)sulfanyl]-N-(naphthalen-1-yl)acetamide | - |
Leishmania major | |
2.7.1.39 | L-threonine | competitive inhibition | Leishmania major | |
2.7.1.39 | additional information | virtual screening of a compound library and docking study, binding free energies, overview | Leishmania major | |
2.7.1.39 | N,N'-(pyridine-2,5-diyl)dicyclohexanecarboxamide | - |
Leishmania major | |
2.7.1.39 | N-[(3r)-adamantan-1-yl]-2-[3-(2-methylphenyl)-6-oxopyridazin-1(6H)-yl]acetamide | - |
Leishmania major |
EC Number | Metals/Ions | Comment | Organism | Structure |
---|---|---|---|---|
2.7.1.39 | Mg2+ | required, binding structure, modelling | Leishmania major |
EC Number | Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
2.7.1.39 | ATP + L-homoserine | Leishmania major | - |
ADP + O-phospho-L-homoserine | - |
? |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
2.7.1.39 | Leishmania major | Q4Q6Y2 | - |
- |
EC Number | Reaction | Comment | Organism | Reaction ID |
---|---|---|---|---|
2.7.1.39 | ATP + L-homoserine = ADP + O-phospho-L-homoserine | possible catalytic mechanism of leishmanial homoserine kinase from molecular simulations | Leishmania major |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
2.7.1.39 | ATP + L-homoserine | - |
Leishmania major | ADP + O-phospho-L-homoserine | - |
? |
EC Number | Subunits | Comment | Organism |
---|---|---|---|
2.7.1.39 | More | the predicted HSK structure contains two distinct domains, the N-terminal domain (1-161, 280-285) and remaining residues constitute the C-terminal domain. The N-terminal domain is formed by two beta-sheets that enclose a core formed of four helices. The active site of HSK is located at the interface of N- and C-domains | Leishmania major |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
2.7.1.39 | HSK | - |
Leishmania major |
EC Number | General Information | Comment | Organism |
---|---|---|---|
2.7.1.39 | additional information | molecular modeling and simulation study of homoserine kinase (HSK) as an effective leishmanial drug target. Two MD simulations are performed on HSK enzyme without substrate (for reference), and on the enzyme in complex with the substrate, prosthetic group, and the magnesium ion using the NAMD program with CHARMM all-atom force field. The topology and parameters for the ligands used in this study are obtained from the MATCH web server. Virtual screening of a compound library and docking study. Homology modeling using several templates, overview. The active site of HSK mainly constitutes of two aspartates, two asparagine residues, and an arginine. All these residues are found to be optimally placed in the predicted model (Asn23, Asp29, Asp144, Asn145, and Arg241). Substrate recognition and structure-function analysis | Leishmania major |